SANTA CLARA, Calif. / Jun 12, 2023 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced they will showcase their significantly expanded InfinityLab GPC/SEC Solution at the HPLC 2023 conference on June 18 – 22, 2023 in Düsseldorf, Germany.
The Agilent InfinityLab GPC/SEC portfolio has become even more comprehensive as it incorporates added value components from recent acquisition of Polymer Standard Service Ltd. (PSS) including a dedicated GPC/SEC Column Thermostat, a Multi-Angle Light Scattering Detector, the GPC/SEC-Ready Kit, and the powerful WinGPC Software into the already existing InfinityLab GPC/SEC Solutions for advanced material characterization.
In combination with Agilent GPC/SEC products like the Bio-GPC/SEC system, High-Temperature GPC system, routine-GPC/SEC software, GPC/SEC columns, standards, and dedicated service offerings this launch of additional products results in the largest one-vendor solution for GPC/SEC.
“We are so pleased to unveil the new GPC/SEC solutions at HPLC,” said Sudharshana Seshadri, vice president of Agilent’s Liquid Chromatography, Mass Spec and Automation divisions. “The combined portfolio of Agilent and PSS delivers a total Agilent solution for the characterization of macromolecules. It enables scientists to update legacy methods, to improve productivity or to address the challenges of characterizing new and innovative high-performance materials for applications within the food, pharmaceutical and biotechnology industries.”
“Our goal at Agilent,” continued Sudharshana Seshadri, “is to deliver the best solutions we can for our customers, considering their current and future needs. Having PSS on board brings unique expertise in serving macromolecular analysis, and combining that with Agilent’s knowledge, and strengths, enables us to address the emerging challenges that customers are facing.”
Also on display, for the first time in Europe at the HPLC 2023 conference, on the Agilent booth #3 will be: 1260 Infinity II Hybrid Multisampler offering unique capabilities for complex samples; the 1290 Infinity II Bio Online Sample Manager which together with the 1290 Infinity II LC systems, creates a high-end PAT-solution, and the Revident Quadrupole Time-of-Flight LC/MS (LC/Q-TOF) System.
Agilent’s second booth #4 will showcase Agilent’s digital lab solutions. Lab optimization strategies will be articulated around key solutions such as efficient data management systems, electronic laboratory notebooks, scientific asset performance management and digital tools designed to track inventories, manage schedules, aggregate data, provide resource visibility, monitor asset performance & utilization, and integrate with other lab systems.
GPC/SEC
Gel Permeation Chromatography / Size Exclusion Chromatography (GPC/SEC) is an important separation technique for synthetic and natural polymers. GPC/SEC analysis is widely used in the chemical-, food-, pharmaceutical- and biopharmaceutical industry and research in applications to determine the molecular weight and size distribution of macromolecules.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.
Last Trade: | US$139.04 |
Daily Change: | 5.37 4.02 |
Daily Volume: | 557,402 |
Market Cap: | US$39.950B |
November 14, 2024 October 21, 2024 September 20, 2024 September 09, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB